Literature DB >> 8761591

Cytokine secretion in vivo and ex vivo following chemotherapy of Mycobacterium tuberculosis infection.

J S Friedland1, J C Hartley, C G Hartley, R J Shattock, G E Griffin.   

Abstract

The human immune response to tuberculosis is partly mediated by the proinflammatory cytokines tumour necrosis factor (TNF), interleukin (IL)-6, and IL-8. We investigated plasma concentrations of these cytokines before and after maximal lipopolysaccharide stimulation ex vivo of whole blood leucocytes from Zambian patients. 32 patients with non-fatal tuberculosis, 25 of whom were seropositive for human immunodeficiency virus (HIV), were followed for 9 months. Patients were assessed at presentation to hospital (visit A), after 2 months' antimycobacterial therapy (visit B), and when chemotherapy was completed (visit C). Between visits A and B, patients regained weight (P = 0.03) and became less anaemic (P = 0.0001). At visit B, haemoglobin concentration remained lower in HIV seropositive patients (P = 0.001) and the erythrocyte sedimentation rate (ESR), initially elevated in all patients, was higher in HIV seropositive patients (100 +/- 6 mm vs. 43 +/- 11 mm in 1 h in seronegative patients; P = 0.002). Plasma IL-8 concentrations were increased at visit C as was IL-8 secretion ex vivo (P < 0.0001 at all time points). Otherwise plasma cytokine levels and secretion ex vivo remained similar throughout the study. Concurrent HIV infection resulted in persistently decreased IL-6 secretions ex vivo although ESR remained high. In summary, after antibiotic therapy in vivo IL-8 secretion ex vivo increased, which supports other data suggesting that IL-8 has a role in immunity to tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761591     DOI: 10.1016/s0035-9203(96)90141-8

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  7 in total

1.  Dysregulated production of interleukin-8 in individuals infected with human immunodeficiency virus type 1 and Mycobacterium tuberculosis.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

2.  Vdelta2+ gammadelta T cell function in Mycobacterium tuberculosis- and HIV-1-positive patients in the United States and Uganda: application of a whole-blood assay.

Authors:  Roxana E Rojas; Keith A Chervenak; Jeremy Thomas; Jamila Morrow; Lorna Nshuti; Sarah Zalwango; Roy D Mugerwa; Bonnie A Thiel; Christopher C Whalen; W Henry Boom
Journal:  J Infect Dis       Date:  2005-10-12       Impact factor: 5.226

3.  The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study.

Authors:  Andrew D Kerkhoff; Robin Wood; Frank G Cobelens; Ankur Gupta-Wright; Linda-Gail Bekker; Stephen D Lawn
Journal:  BMC Med       Date:  2015-04-02       Impact factor: 8.775

4.  Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa.

Authors:  Andrew D Kerkhoff; Robin Wood; Frank G Cobelens; Ankur Gupta-Wright; Linda-Gail Bekker; Stephen D Lawn
Journal:  BMC Infect Dis       Date:  2014-12-21       Impact factor: 3.090

Review 5.  Effector Mechanisms of Neutrophils within the Innate Immune System in Response to Mycobacterium tuberculosis Infection.

Authors:  Eric Warren; Garrett Teskey; Vishwanath Venketaraman
Journal:  J Clin Med       Date:  2017-02-07       Impact factor: 4.241

Review 6.  It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity.

Authors:  Sasha E Larsen; Brittany D Williams; Maham Rais; Rhea N Coler; Susan L Baldwin
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

7.  Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis.

Authors:  Cesar A Ugarte-Gil; Paul Elkington; Robert H Gilman; Jorge Coronel; Liku B Tezera; Antonio Bernabe-Ortiz; Eduardo Gotuzzo; Jon S Friedland; David A J Moore
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.